Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056131 | 0.78 | NQO2 (0.33) | KDRNQO2ADCY1RAB9AHSD17B1 | |
| SCHEMBL13055747 | 0.75 | NPC1 (0.45) | NPC1RAB9AHSD17B1LMNAMEN1 | |
| SCHEMBL13055887 | 0.73 | KDR (0.36) | KDRNQO2NPC1RAB9ALMNA | |
| SCHEMBL13056079 | 0.70 | LMNA (0.42) | NQO2NPC1RAB9AHSD17B1LMNA | |
| SCHEMBL13055813 | 0.69 | P2RX1 (0.50) | KDRMEN1KMT2A | |
| SCHEMBL13056184 | 0.68 | MEN1 (0.35) | KDRNQO2NPC1RAB9AHSD17B1 | |
| SCHEMBL15649255 | 0.63 | KDM4E (0.55) | HDAC1NQO2NPC1RAB9ALMNA | |
| SCHEMBL17295638 | 0.61 | NQO2 (0.60) | NQO2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL201236 | 0.61 | CA5A (0.70) | HSD17B1LMNAMEN1KMT2A | |
| SCHEMBL10546235 | 0.60 | CES2 (0.44) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9126992-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
| WO-2010132404-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | HDAC1 998/4885KDR 2958/4885NQO2 2230/4885 |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | HDAC1 998/4885KDR 2958/4885NQO2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.